Virtu Financial’s Silexion Therapeutics SLXN Stock Holding History

Virtu Financial’s Portfolio SLXN Stock Details SLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-95	Closed	-$12K	–	2222
2025 Q2	$12K	Buy	+95	New	+$12.9K	﹤0.01%	1310
2024 Q4	–	Sell	-20	Closed	-$14K	–	2190
2024 Q3	$14K	Buy	+20	New	+$31.4K	﹤0.01%	1167

Other funds holding SLXN

Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

Virtu Financial's SLXN Position: Q3 2025 in Review

Virtu Financial sold out of Silexion Therapeutics (SLXN) in Q3 2025, closing a stake of 95 shares — an estimated $12K sold.

Virtu Financial first reported a position in SLXN in Q3 2024 and held it in 2 quarters. The position peaked at $14K in Q3 2024. 4 funds tracked by Wall St. Rank hold SLXN as of Q3 2025.

Virtu Financial reported no remaining Silexion Therapeutics position as of Q3 2025 after selling out during the quarter.
Virtu Financial sold 95 Silexion Therapeutics shares in Q3 2025, an estimated $12K.
Virtu Financial first reported a position in Silexion Therapeutics in Q3 2024 and held it in 2 quarters.
Virtu Financial's Silexion Therapeutics position peaked at $14K in Q3 2024.
4 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.